Program – 62th Days H.P. Klotz – 2019
 |
« New insights into the pathophysiology and treatment of Neuroendocrine Tumors« |
Thursday, June 20th, 2019
08H45-09H00 : Introduction
PRECLINICAL MODELS OF NEUROENDOCRINE TUMORS
- 09H00-09H30: Cell lines and primary cultures
David Romano, Marseille, France - 09H30-10H00: Zebrafish
Giovanni Vitale, Milan, Italy - 10H00-10H30: Murine models
Natalia Pellegata, Neuherberg, Germany
10H30-11H00 : Coffee break – Posters
PATHOLOGY, GENOMICS AND EPIGENOMICS OF NEUROENDOCRINE TUMORS
- 11H00-11H30: GEP and thoracic neuroendocrine tumors.
Aldo Scarpa, Verone, Italy - 11H30-12H00: Emerging Molecular Markers of Metastatic Pheochromocytomas and Paragangliomas
Luis Jaime Castro-Vega, Paris, France - 12H00-12H30: Epigenomics in neuroendocrine tumors.
Leo Hofland, Rotterdam, The Netherlands
12H30-14H00 : Lunch
DIAGNOSIS OF NEUROENDOCRINE NEOPLASMS
- 14H00-14H30: Lung and digestive neuroendocrine neoplasms: from WHO classification to biomarker screening: which perspective?
Jean-Yves Scoazec, Villejuif, France - 14H30-15H00: Biomarkers: are hormone validated tumor biomarkers ?
Wouter de Herder, Rotterdam, The Netherlands - 15H00-15H30: Receptor Radionuclide imaging for diagnosis and therapy.
Frédéric Courbon, Toulouse, France
15H30-16H00 : Coffee break – Posters
PROGRESS IN THE DIAGNOSIS AND MANAGEMENT OF GEP NEOPLASMS
- 16H00-16H30: Digestive system mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN)
Louis De Mestier, Paris, France - 16H30-17H00: French and ENETS Consensus Guidelines
Guillaume Cadiot, Reims, France
Friday, June 21st, 2019
DEBATE ON THE TREATMENT OF GEP NEOPLASMS
- 9H00-9H30: Role of surgery
Alain Sauvanet. Paris, France - 09H30-10H00: Role of radiofrequency ablation
Marc Barthet. Marseille, France
ORAL COMMUNICATIONS
- 10H00-10H30: Oral communications
10H30-11H00 : Coffee break
MANAGEMENT OF AGGRESSIVE NEUROENDOCRINE NEOPLASMS: NOVEL PERSPECTIVES IN MEDICAL TREATMENT
- 11H00-11H30: Aggressive GEP neoplasms
Romain Coriat, Paris, France - 11H30-12H00: Aggressive lung and thymic neoplasms
Piero Ferolla, Perugia, Italy - 12H00-12H30: Malignant Pheochromocytomas and paragangliomas
Julien Hadoux, Villejuif, France
12H30-14H00 : Lunch
MEDULLARY THYROID CANCER
- 14H00-14H30: Clinical utility of genetic diagnosis for sporadic and hereditary MTCs
Rossella Elisei, Pisa, Italy - 14H30-15H00: Baseline and stimulated Calcitonin: Thresholds for the diagnosis of medullary thyroid cancer
Laura Fugazzola, Milan, Italy - 15H00-15H30: State of the art of medical therapies
Eric Baudin, Villejuif, France
MULTIPLE ENDOCRINE NEOPLASIA TYPE 1
- 15H30-16H00: Update on phenotypes of MEN1 mutation carriers
Gerlof Valk, Utrecht, The Netherlands - 16H00-16H40: ROUND TABLE DISCUSSION: Clinical screening of MEN1 mutations carriers: When and how screening should be performed?
Discussants: Brigitte Delemer, Reims; Catherine Cardot, Lille; Antoine Tabarin, Bordeaux, France
16H40-16H50 : Conclusion
© SFE Janvier 2019